Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray

Table 1 Oligonucleotides used in this study

##	Sequence (5'-3')	Application
C1	CACATGGCTGCCCAGTGTCAGCTTC	Primers used to amplify exon3 and exon7 fragments of
C2*	GGCCACCCCTGAAATGTTTCCAAG	CYP2C9 containing SNP sites. C2* and C4* were
C3	ACGTGTGATTGGCAGAAACCGGAGC	fluorescein (Cy3) labeled at 5'end.
C4*	GGGACTTCGAAAACATGGAGTTGCAG
C1Tf	ATTGAGGACTGTGTTCAAGAGGAAGC	Primers used to construct mutant templates.
C1Tr	CTTCCTCTTGAACACAGTCCTC	The variant bases (indicated by underlines)
C2Tf	CCTACACAGATGCTGTGGTGCAC	were introduced when synthesized.
C2T1	CTGGTGGGGAGAAGGTCAAGGTATCTC
C2T2	CTGGTGGGGAGAAGGTCAGTGTATCTC
C2T3	CTGGTGGGGAGAAGCTCAATGTATCTC
P1	TTGAGGACCGTGTTCAA-spacer-NH2	Pairs of probes with one base difference (indicated
P2	TTGAGGACTGTGTTCAA-spacer-NH2	with underline) for SNP discrimination, immobilized
P3	GAGATACATTGACCTTC-spacer-NH2	on aldehyde-coated slides surface with
P4	GAGATACCTTGACCTTC-spacer-NH2	3'end primary NH2 group.
P5	GAGATACATTGACCTTC-spacer-NH2
P6	GAGATACACTGACCTTC-spacer-NH2
P7	TACATTGACCTTCTCC-spacer-NH2
P8	TACATTGAGCTTCTCC-spacer-NH2

Table 2 CYP2C9 allele frequency in the study population

Allele	Number of alleles	Frequency %
*2	0/124	0
*3	7/124	5.6
*4	0/124	0
*5	0/124	0

Table 3 Therapeutic outcome of Irbesartan in wild type group and CYP2C9*1/*3 group

	Effective	Failed
Wild type	43	12
CYP2C9*1/*3	6	1

P > 1 (χ² test), no significant difference in the odd of effectiveness of Irbesartan between wild type group and CYP2C9*1/*3 group.